Summary A number of genes are known to be involved in inherited susceptibility to breast and/or ovarian cancer. In the context of high-risk families the most important genes are BRCAJ on chromosome 17q, which is associated with a high penetrance of both breast and ovarian cancer, and BRCA2 on chromosome 13q, which causes a high risk of breast cancer but a lower risk of ovarian cancer. Other high-risk cancer genes that confer increased risks of breast or ovarian cancer in addition to other cancers include the hereditary non-polyposis colorectal cancer genes and the TP53 gene, which causes breast cancer as part of the Li-Fraumeni syndrome. The predisposing mutations in these genes are relatively rare in the population. More common genes which are associated with an increased, but lower, risk of breast cancer are the ataxiatelangiectasia gene and the HRASI gene. This paper reviews recent progress in mapping and cloning of these susceptibility genes, and provides estimates of the cancer risks associated with each gene and the frequency of predisposing mutations.
An inherited component to common cancers has been suspected for many years because of anecdotal reports of families with large numbers of affected individuals. Both breast and ovarian cancer were recognised as clustering in some families over 100 years ago (Broca, 1866; Olshausen, 1877) . More recently systematic epidemiological studies of familial risks have demonstrated that most common cancers occur more frequently in first-degree relatives of cancer patients with the same type of cancer than in the general population. The overall relative risk of breast or ovarian cancer in first-degree relatives of individuals affected at the same site is 2-to 3-fold (Houlston and Peto, 1995) and much higher relative risks are observed if attention is restricted to breast cancer cases occurring at an early age (Claus et al., 1990a) . (An age-at-onset effect has not been established for ovarian cancer). Families with several cases of both types have also been described (Lynch et al., 1972) . The risk of ovarian cancer is moderately increased, of the order 1.3-to 1.7-fold, in the relatives of breast cancer patients and vice versa (Schildkraut et al., 1989; Goldgar et al., 1994a; Easton et al., 1995; Peto et al., 1995) , suggesting the existence of genes predisposing to both cancers.
A number of segregation analyses on pedigrees ascertained through a breast cancer proband have been performed and most have provided evidence for the presence of a rare dominant breast cancer gene conferring a high risk (e.g. Claus et al., 1991) . A segregation analysis of 518 families ascertained through an ovarian cancer proband with at least one affected relative also favoured a rare dominant gene (Houlston et al., 1991) .
The inherited basis of certain families with a high risk of breast and/or ovarian cancer has now been confirmed with the identification or localisation of susceptibility genes. These genes, which are the principal subject of this review, are summarised in Table I 1990 (Hall et al., 1990 and has recently been cloned (Miki et al., 1994) . BRCA2, a predominantly breast cancer gene, has now been localised to chromosome 13q by linkage analysis (Wooster et al., 1994) . Other high risk cancer genes which confer elevated risks of breast or ovarian cancer in addition to other cancers include the genes responsible for the hereditary non-polyposis colorectal cancer syndrome, which predisposes predominantly to colorectal and endometrial cancer but also has an associated increased ovarian cancer risk (Leach et al., 1993; Watson and Lynch, 1993; Bronner et al., 1994; Papadopoulos et al., 1994) and the TP53 gene on chromosome 17p, which causes premenopausal breast cancer as part of the Li-Fraumeni syndrome (Li et al., 1988; Malkin et al., 1990) .
Predisposing mutations in these genes are all rare and are therefore unlikely to account for more than a small minority of total breast and ovarian cancer incidence except at very young ages. The ataxia-telangiectasia gene (Gatti et al., 1988; Swift et al., 1991) (Stratton et al., 1994) . Interestingly in the subgroup of 12 families containing male and female breast cancer and at least one ovarian cancer the evidence against linkage was also strong with an estimated 0% of families linked (95% CL 0-29%). Several of these families are now known to be due to BRCA2 (see below).
Associated breast and ovarian cancer risks In the future it should be possible to estimate directly the cancer risks conferred by BRCAI by studying gene carriers identified through large population-based studies. In the meantime, estimates have been derived from the data collected on linkage families using two essentially independent methods, namely maximising the LOD score over possible penetrance functions and using the incidence of second breast or ovarian cancers following a first breast cancer. Using either approach the overall lifetime risk of breast or ovarian cancer was estimated as close to 100% (Ford et al., 1994; Easton et al., 1995) . Using the maximum LOD score method (assuming no heterogeneity of risk between families) the estimated cumulative risk for breast cancer rose to 51% by age 50 (95% CL 25-67%) and 85% by age 70 (95% CL 51-95%). The corresponding estimates for ovarian cancer were 23% by age 50 (95% CL 5-38%) and 63% by age 70 (95% CL 25-82%). Up to age 60 the second cancer data gave somewhat higher risks, possibly reflecting individual variation in risk due to other genetic or environmental factors or a tendency to ascertain families with individuals with double primary cancers, but neither the overall cumulative risk by age 70 nor the site-specific risks by age 70 differed between the studies. The largest BRCAJ family to be reported in the literature, which contains some 30 breast cancers and 20 ovarian cancers, has also been analysed using lifetable analysis and provides further evidence for the highGenetcs of breast and ovarian cancer D Ford and DF Easton 807 lifetime risk estimates of breast and ovarian cancers (Goidgar et al., 1994b 
Hereditary non-polyposis colorectal cancer genes
Hereditary non-polyposis colorectal cancer (HNPCC) is a dominant familial cancer syndrome which predisposes to colon cancer, and to a lesser extent, cancers at other sites including endometrium, stomach, small bowel and ovary. Watson and Lynch (1993) estimated the risk of ovarian cancer in members of 23 HNPCC kindreds to be approximately 4-fold greater than in the general population. The true relative risk will be slightly higher since not all those individuals studied will be carriers of the deleterious gene. The median age of diagnosis was 40 years, which is considerably lower than the median age of diagnosis in the general population and in interesting contrast to ovarian cancers within BRCAI-linked families. There was some evidence that the ovarian cancer risk differed between families.
It is now known that HNPCC can result from germline mutations in a class of DNA repair genes originally identified in yeast. To date, four such genes are known to cause HNPCC, namely the hMSH2, hMLHI, hPMSI and hPMS2 genes on chromosomes 2p, 3p and 7p (Leach et al., 1993; Bronner et al., 1994; . However it is unclear whether all of these genes confer an increased risk of ovarian cancer.
The frequency of these HNPCC mutations is the subject of some debate. Some reports have suggested that as much as 20% of colorectal cancer could be due to mutations in these genes. These estimates are based on the proportions of colorectal tumours exhibiting the microsatellite instability phenotype, which is common in HNPCC families. However, most of these tumours are likely to be sporadic and as yet there is no evidence that this phenotype is invariably the result of germline mutations in mismatch repair genes. Clinical studies suggest that the HNPCC syndrome probably only accounts for 1% or less of colorectal cancer (Bodmer et al., 1994; Aaltonen et al., 1994) , suggesting a population frequency of the order of one in 10 000. (Li et al., 1988) . Germline mutations in the TP53 gene have been identified in over 50% of LFS families and in a number of families with some but not all of the features of the classical LFS (Malkin et al., 1990; Eeles, 1993 (Jolly et al., 1994) , it is now clear that most breast-ovarian families are caused by BRCAJ and some, possibly all, of the remainder are due to BRCA2. In population based studies of breast cancer cases TPS3 germline mutations have been found in less than 1% of cases, even at young ages (Borresen et al., 1992; Sidransky et al., 1992) .
Other breast cancer genes with high penetrance There are a number of families characterised by early-onset female breast cancer and/or male breast cancer which show evidence against linkage to both BRCAJ and BRCA2 (Wooster et al., 1994; MR Stratton, R Wooster and DE Goldgar, personal communication) . It seems possible, therefore, that at least one more breast cancer gene with high penetrance remains to be discovered. It should be noted, however, that some of these apparently unlinked families will be due to BRCAJ or BRCA2, but appear unlinked because of young sporadic cases occurring by chance. Indeed BRCAJ mutations have been found in a number of such families (DE Goldgar, personal communication) . A formal study to estimate the proportion of high-risk families not accounted for by BRCAJ and BRCA2 is currently being conducted by the BCLC.
The ataxia-telangiectasia gene Ataxia-telangiectasia (AT) is an autosomal recessive disorder characterised by cerebellar ataxia, oculocutaneous telangiectasia, a hypersensitivity to ionising radiation and an increased susceptibility to cancer (McKinnon, 1987; Sedgwick and Boder, 1991) . The frequency of the AT gene, which is located on chromosome llq22-23, is likely to be of the order of 0.005 , suggesting that about 1% of the population are heterozygous for AT.
A number of studies have shown that female relatives of AT patients are at an increased risk of breast cancer. , in a review of four published studies (Swift et al., 1987; Pippard et al., 1988; Borresen et al., 1990; Swift et al., 1991) , estimated that the relative risk of breast cancer to AT heterozygotes is 3.9 fold (95% CL 2.1-7.2). A gene conferring such a low relative risk would not, on the whole give rise to multiple early-onset case families. For example, assuming a relative risk of 3.9 and a gene frequency of 0.005 between 40 and 60 and 1 above age 60, AT could be responsible for 8% of cases under 40 and 2% of cases between 40 and 60.
HRASI
The proto-oncogene HRASJ is tightly linked to a minisatellite locus, which has some 30 alleles of which four represent 94% of all alleles in whites, the remainder being rare (Capon et al., 1983; Krontiris et al., 1986; Krontiris, 1990) . A metaanalysis of 23 studies has shown a highly significant association of rare HRASJ alleles with cancer (Krontiris et al., 1993) . It is undetermined as yet whether the HRASJ gene itself or a closely linked gene is responsible for the association; if it is due to the HRASI gene, the mechanism underlying the association is completely unclear. Sites for which significant associations were found were breast, colorectum, urinary bladder and acute leukaemia. The relative risk of breast cancer associated with rare HRASJ alleles was 1.68 (95% CL 1.23-2.29), and the authors estimated that as many as 1 in 11 breast cancers might be attributed to this factor.
Conclusions
Studies of multiple-case families have led to the identification of highly penetrant genes which predispose to breast and ovarian cancer. BRCAJ and BRCA2 appear to account for the majority of large multiple-case families, but it is less clear to what extent they account for the more common, smaller breast and ovarian cancer families such as pairs of affected relatives, since these could be due to lower penetrance genes.
For BRCAJ at least, it should now be possible to answer this question directly.
From a genetic counselling standpoint it is already possible to identify women in families linked to BRCAJ and to counsel them on the basis of linkage data and reasonably precise estimates of cancer risk. Now that BRCAJ has been cloned it may not be long before direct testing for BRCAJ mutations becomes practical on a routine basis in high-risk women. However, it is already clear that mutations will be widely scattered throughout the gene, thus testing on a large scale is likely to be laborious and it will be difficult to exclude the presence of a mutation. This, combined with the rarity of BRCAI mutations makes it unlikely that testing in the general population will be useful, other than for research purposes. Intense efforts will now be made to clone BRCA2. If BRCA2 is homologous to BRCAI or is one of the candidate genes already identified, BRCA2 may be cloned very quickly, otherwise the time scale involved is indeterminate. In the meantime risk estimates for BRCA2 should be available soon, allowing women in BRCA2-linked families to have counselling on the basis of genotyping. Epidemiological studies are currently being conducted by the BCLC to assess whether or not the risks of breast and ovarian cancer in BRCA1 carriers are substantially modified by other risk factors such as parity, age at first birth and oral contraceptive use. From a practical point of view the most important risk factor is oral contraceptive use. In the general population long-term oral contraceptive use is known to reduce substantially the risk of ovarian cancer (Parazzinni et al., 1991) but to increase slightly the risk of breast cancer at young ages (UK National Case-Control Study Group, 1990) , so their use in BRCAJ carriers might cause a marked increase or decrease in overall cancer risk. Similar studies of BRCA2 carriers will also be important.
Taken together the high penetrance genes (BRCAJ, BRCA2, TP53 and the HNPCC genes) are likely to account for considerably less than 10% of all breast and ovarian cancer cases in the population. Common susceptibility genes could account for a much higher proportion of cancers in the general population but would necessarily confer much lower lifetime risks. The HRASJ minisatellite locus is an example of a common, low penetrant gene which causes breast cancer but others may exist. The identification and understanding of such genes (if they exist) would be of great practical importance, possibly leading to genetic testing as an adjunct to screening for common cancers. However, low penetrant genes will not cause multiple case families and may not even give rise to a detectably increased risk in relatives of cancer patients; thus they are likely to be difficult to detect by finkage and will only be identified through associations of cancer risk with other heritable phenotypes (as in the case of AT), or through direct testing of candidate genes.
